{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:05:26Z","timestamp":1791198326625,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1097\/inf.0b013e31823f0e11","type":"journal-article","created":{"date-parts":[[2011,11,26]],"date-time":"2011-11-26T00:24:04Z","timestamp":1322267044000},"page":"384-388","source":"Crossref","is-referenced-by-count":15,"title":["Recovery From Lipodystrophy in HIV\u2013infected Children After Substitution of Stavudine With Zidovudine in a Non-nucleoside Reverse Transcriptase Inhibitor\u2013based Antiretroviral Therapy"],"prefix":"10.1097","volume":"31","author":[{"given":"Linda","family":"Aurpibul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sineenart","family":"Taejaroenkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thira","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virat","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210202","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R2-13-20210202","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa011157","article-title":"Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.","volume":"345","author":"Gortmaker","year":"2001","journal-title":"N Engl J Med"},{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/423178","article-title":"Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.","volume":"39","author":"Viani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00006454-200205000-00011","article-title":"Lipodystrophy syndrome in human immunodeficiency virus-infected children.","volume":"21","author":"Amaya","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R6-13-20210202","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.qai.0000178930.93033.f2","article-title":"Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children.","volume":"40","author":"Beregszaszi","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-13-20210202","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00431-004-1610-y","article-title":"Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.","volume":"164","author":"Sanchez Torres","year":"2005","journal-title":"Eur J Pediatr"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000230523.94588.85","article-title":"Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy.","volume":"43","author":"Dzwonek","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R9-13-20210202","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(05)77775-8","article-title":"Abnormal fat distribution and use of protease inhibitors.","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00126334-200209010-00007","article-title":"Swiss HIV Cohort Study. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study.","volume":"31","author":"Bernasconi","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","article-title":"APROCO Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.","volume":"15","author":"Duran","year":"2001","journal-title":"AIDS"},{"key":"R13-13-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpedi.157.3.249","article-title":"Adolescent Medicine HIVAIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.","volume":"157","author":"Murphy","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R14-13-20210202","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1177\/135965350701200811","article-title":"Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.","volume":"12","author":"Aurpibul","year":"2007","journal-title":"Antivir Ther (Lond)"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"R23-13-20210202","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Mitochondrial Toxicity Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1542\/peds.111.3.e275","article-title":"First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.","volume":"111","author":"McComsey","year":"2003","journal-title":"Pediatrics"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e3283420eef","article-title":"Pathogenesis and treatment of HIV lipohypertrophy.","volume":"24","author":"Leung","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"R29-13-20210202","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1468-1293.2008.00560.x","article-title":"Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.","volume":"9","author":"Aurpibul","year":"2008","journal-title":"HIV Med"},{"key":"R31-13-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/tropej\/fmn080","article-title":"Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India.","volume":"55","author":"Kumarasamy","year":"2009","journal-title":"J Trop Pediatr"},{"key":"R32-13-20210202","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/QAI.0b013e318158c08e","article-title":"Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes.","volume":"46","author":"Zhang","year":"2007","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006454-201204000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:31Z","timestamp":1786047871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201204000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31823f0e11","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}